FDA Approves Isembyld (apitegromab-mstn) Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (SMA)
RegulatoryapprovedIsembyldPositive
AI Analysis
Summary
Scholar Rock's Isembyld (apitegromab-mstn) received FDA approval for treating spinal muscular atrophy in children and adults. This represents a significant regulatory milestone for the muscle-targeted therapy.
Outcome Details
FDA approval for Isembyld (apitegromab-mstn) for SMA
Importance:9/10
Sentiment:
0.95
FDA ApprovalRare DiseaseNeuromuscularPediatricAdultMuscle-Targeted Treatment
Related Companies
Read the original article
Published by Drugs.com New Drug Approvals on September 11, 2026 11:09 PM